Literature DB >> 33587497

Finding the Optimal Alternative for Immediate Hypersensitivity to Low-Osmolar Iodinated Contrast.

Kyoung-Hee Sohn, Jang-Ho Seo, Dong-Yoon Kang1, Suh-Young Lee, Hye-Ryun Kang.   

Abstract

OBJECTIVES: Avoiding culprit agents is recommended for subjects who have had previous hypersensitivity reaction (HSR) to low-osmolar contrast media (LOCM). However, the guidelines for choosing optimal alternatives have not been determined. We investigated the outcomes of reexposure in patients with previous immediate HSRs to provide a safe option.
MATERIALS AND METHODS: The outcomes of reexposure were assessed in a cohort with previous LOCM-associated HSR based on skin testing results and the presence of a common N-(2,3-dihydroxypropyl) carbamoyl side chain.
RESULTS: Among 482 skin tests, 38.7% (31/80), 45.8% (99/216), and 64.0% (119/186) of mild, moderate, and severe index HSRs showed positivity to at least 1 LOCM, of which 62.8% showed positivity to at least 2 different LOCM. The overall recurrent HSRs were reduced from 43.8% upon reexposure to the culprit LOCM to 12.3% upon using nonculprit skin test negative LOCM (P = 0.004); those with severe index HSRs exhibited a significant reduction (11.3% vs 100%), but those with non-severe HSRs to LOCM did not. In subjects with severe index HSRs, the skin test cross-reactivity between LOCM was associated with sharing the common side chain (20.7% vs 11.5%, P = 0.003), and the recurrence rate of HSRs was effectively reduced by avoiding the common side chain (24.0% vs 7.8%, P = 0.039). However, these differences were not observed in those with non-severe index HSRs.
CONCLUSIONS: In patients who experienced a severe index HSR to LOCM, skin test negative LOCM without a common side chain could be suggested as an option for safe reexposure.
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.

Entities:  

Year:  2021        PMID: 33587497     DOI: 10.1097/RLI.0000000000000765

Source DB:  PubMed          Journal:  Invest Radiol        ISSN: 0020-9996            Impact factor:   6.016


  2 in total

Review 1.  Diagnosis and Prevention of Hypersensitivity Reactions to Iodinated Contrast Media.

Authors:  Hye-Ryun Kang; Jiung Jeong; Knut Brockow
Journal:  Allergy Asthma Immunol Res       Date:  2022-07       Impact factor: 5.096

2.  Risk of Hypersensitivity Reactions to Iopromide in Children and Elderly: An Analysis of 132,850 Patients From 4 Observational Studies and Pharmacovigilance Covering >288 Million Administrations.

Authors:  Jan Endrikat; Julia Chernova; Christoph Gerlinger; Marcin Pracz; Philipp Lengsfeld; Aasia Bhatti; Alexander Michel
Journal:  Invest Radiol       Date:  2022-05-01       Impact factor: 6.016

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.